Schizophrenia
6
Companies
12
Drug Programs
5
Phase 3
0
Upcoming PDUFAs
Teva Pharmaceutical Industries
Olanzapine
Teva Pharmaceutical Industries
olanzapine
PharmaMar, S.A.
Tryptophan
Intra-Cellular Therapies, Inc.
ITI-007
Intra-Cellular Therapies, Inc.
Lumateperone 42 mg
Johnson & Johnson
paliperidone ER Oros
Johnson & Johnson
Paliperidone ER
Johnson & Johnson
JNJ-37822681
Johnson & Johnson
R092670
Eli Lilly and Company
LY2140023
ACADIA Pharmaceuticals Inc.
ACP-104
Teva Pharmaceutical Industries
risperidone
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| TEVA Teva Pharmaceutical Industries | Olanzapine | Approved | — | — | — |
| TEVA Teva Pharmaceutical Industries | olanzapine | Approved | — | — | — |
| PHM.MC PharmaMar, S.A. | Tryptophan | Phase 3 | — | — | — |
| ITCI Intra-Cellular Therapies, Inc. | ITI-007 | Phase 3 | — | — | — |
| ITCI Intra-Cellular Therapies, Inc. | Lumateperone 42 mg | Phase 3 | — | — | — |
| JNJ Johnson & Johnson | paliperidone ER Oros | Phase 3 | — | — | — |
| JNJ Johnson & Johnson | Paliperidone ER | Phase 3 | — | — | — |
| JNJ Johnson & Johnson | JNJ-37822681 | Phase 2 | — | — | — |
| JNJ Johnson & Johnson | R092670 | Phase 2 | — | — | — |
| LLY Eli Lilly and Company | LY2140023 | Phase 2 | — | — | — |
| ACAD ACADIA Pharmaceuticals Inc. | ACP-104 | Phase 2 | — | — | — |
| TEVA Teva Pharmaceutical Industries | risperidone | — | — | — | — |
Not financial advice
Signals are probabilistic and based on historical data — past performance doesn't guarantee future results. Do your own research.